Atlantic Trust Group LLC increased its stake in shares of Zoetis Inc (NYSE:ZTS) by 8.4% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 102,747 shares of the company’s stock after buying an additional 7,919 shares during the quarter. Atlantic Trust Group LLC’s holdings in Zoetis were worth $6,550,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the business. AXA grew its stake in Zoetis by 15.2% in the 3rd quarter. AXA now owns 252,241 shares of the company’s stock valued at $16,083,000 after purchasing an additional 33,227 shares during the period. Steward Partners Investment Advisory LLC bought a new position in Zoetis in the 3rd quarter valued at $114,000. Garde Capital Inc. bought a new position in Zoetis in the 3rd quarter valued at $419,000. Cetera Advisors LLC bought a new position in Zoetis in the 3rd quarter valued at $211,000. Finally, Yellowstone Partners LLC bought a new position in Zoetis in the 3rd quarter valued at $694,000. Hedge funds and other institutional investors own 93.19% of the company’s stock.

A number of brokerages have issued reports on ZTS. Cantor Fitzgerald set a $80.00 price objective on Zoetis and gave the company a “buy” rating in a research note on Tuesday, December 12th. Morgan Stanley upgraded Zoetis from an “equal weight” rating to an “overweight” rating and set a $80.00 price objective for the company in a research note on Wednesday, November 29th. UBS Group restated a “neutral” rating on shares of Zoetis in a research note on Friday, November 24th. Cowen set a $80.00 price target on Zoetis and gave the stock a “buy” rating in a research note on Friday, November 17th. Finally, Jefferies Group reiterated a “buy” rating on shares of Zoetis in a research note on Friday, November 10th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have given a buy rating to the company’s stock. Zoetis currently has a consensus rating of “Buy” and an average price target of $68.53.

Zoetis Inc (ZTS) opened at $71.99 on Tuesday. The company has a debt-to-equity ratio of 2.45, a quick ratio of 1.95 and a current ratio of 2.80. The firm has a market capitalization of $35,221.20, a price-to-earnings ratio of 37.89, a PEG ratio of 2.17 and a beta of 1.06. Zoetis Inc has a 12 month low of $52.00 and a 12 month high of $73.58.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.02. The company had revenue of $1.35 billion during the quarter, compared to the consensus estimate of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm’s quarterly revenue was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.52 EPS. research analysts forecast that Zoetis Inc will post 2.37 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, March 1st. Investors of record on Friday, January 19th will be issued a dividend of $0.126 per share. This is a boost from Zoetis’s previous quarterly dividend of $0.11. The ex-dividend date is Thursday, January 18th. This represents a $0.50 dividend on an annualized basis and a yield of 0.70%. Zoetis’s dividend payout ratio is 22.11%.

ILLEGAL ACTIVITY NOTICE: “Atlantic Trust Group LLC Buys 7,919 Shares of Zoetis Inc (ZTS)” was first published by TheOlympiaReport and is owned by of TheOlympiaReport. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at

Zoetis Profile

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with Analyst Ratings Network's FREE daily email newsletter.